In summary, our work sheds light on the molecular etiology of GNAO1 encephalopathy, identifies the neomorphic intermediates of the disease dominance, provides a much-needed biomarker for assessment of disease severity, and might pave the way for future drug discovery for this disorder. The gene discussed is GNAO1; the disease is Encephalopathy.